Moderna is trading at $147.38 (-4.46%), as investors may be taking profits after the melanoma-vaccine surge.
- It is reversing part of its 9.93% gain from September 1 after an exceptionally volatile biotech rally; comparable coverage described earlier pullbacks as profit-taking and valuation concerns.
- The completed $3.0 billion convertible-notes offering leaves a dilution and financing overhang; no new September 2 company-specific catalyst was identified.
- The decline is occurring despite biotech and major indexes trading higher.